Vaccine process: from lab to you
New vaccines are first developed in laboratories. The virus that causes COVID-19 is related to other coronaviruses that cause diseases such as severe acute respiratory syndrome (SARS) and Middle East respiratory syndrome (MERS). Long before SARS-COV-2 was identified, scientists had been studying these other coronaviruses for years to develop a vaccine against them. The knowledge gained through previous research on coronavirus vaccines helped accelerate the early development of current COVID-19 vaccines.
After initial development, undergo vaccines Three stages of clinical trials To ensure that they are safe and effective. For other vaccines routinely used in the United States, three stages of clinical trials are performed one at a time. During the development of COVID-19 vaccines, these steps have overlapped to speed up the process so that vaccines can be used as quickly as possible to control the epidemic. No test phase is omitted.
Clinical trials of COVID-19 vaccines have included thousands of volunteers of various ages, ethnicities, and breeds. Clinical trials for vaccines compare results (such as how many people become ill) between vaccinated people and those people. Because COVID-19 continues to be widespread, vaccine clinical trials have been conducted more rapidly than if the disease were less common. The results of these tests showed that COVID-19 vaccines are effective. They have shown no serious safety concerns after more than 8 weeks after vaccination. This is an important milestone, as it is unusual for adverse effects caused by vaccines after this time.
Emergency use authority
Before vaccines are made available to people in real-world settings, the FDA assesses findings derived from clinical trials. So far, they have determined Three COVID-19 vaccines Those vaccines meet FDA’s safety and effectiveness standards and are permitted Emergency Use Authority (EUAs)External icon. The EUA has allowed vaccines to be distributed quickly for use while maintaining the same safety standards required for all vaccines. Learn more in Video about the European Union.
Manufacturing and distribution
The US government has invested substantial resources for both manufacturing and distribution of COVID-19 vaccines. This has allowed manufacturing to begin when vaccines are still in the third phase of clinical trials to begin delivery as soon as the FDA has authorized each vaccine.
Tracking Security Using Vaccine Monitoring Systems
As vaccines are distributed outside of clinical trials, many surveillance systems continue to track them to ensure their safety. Millions of people have received COVID-19 vaccines, and are reassuring the results of ongoing vaccine safety surveillance efforts. Some people have no side effects. Many people have reported mild Side effects after COVID-19 vaccination, Such as pain or swelling at the injection site, headache, chills, or fever. These reactions are common. A small number of people Severe allergic reaction (Called “anaphylaxis” after vaccination), but it is extremely rare. If this happens, vaccination providers have medications available to treat the response effectively and immediately.
No unexpected patterns of reactions or other safety concerns have been identified during initial vaccine safety monitoring. The CDC and FDA continue to closely monitor many reporting systems, such as the Vaccine Adverse Event Reporting System (VARS), Vaccine Safety Datalink (VSD), and V safe, Who now help in the search for any safety issues, so that vaccines are being given to patients in real-world settings across the country.
What does it mean to you
COVID-19 vaccines have been rapidly developed and distributed to help fight epidemics. During this process, all steps have been taken to ensure their safety and effectiveness. The CDC advises you to get a COVID-19 vaccine as soon as it is available to you so that you can protect yourself and others.
Source link: https://tools.cdc.gov/api/embed/downloader/download.asp?m=404952&c=419415